190 related articles for article (PubMed ID: 29792808)
21. TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of γδ T cells.
Guo Q; Zhao P; Zhang Z; Zhang J; Zhang Z; Hua Y; Han B; Li N; Zhao X; Hou L
Cancer Immunol Immunother; 2020 Dec; 69(12):2571-2587. PubMed ID: 32588076
[TBL] [Abstract][Full Text] [Related]
22. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma.
Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH
Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821
[No Abstract] [Full Text] [Related]
23. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
[TBL] [Abstract][Full Text] [Related]
24. Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma.
Salnikov AV; Groth A; Apel A; Kallifatidis G; Beckermann BM; Khamidjanov A; Ryschich E; Büchler MW; Herr I; Moldenhauer G
J Cell Mol Med; 2009 Sep; 13(9B):4023-33. PubMed ID: 20196789
[TBL] [Abstract][Full Text] [Related]
25. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
[TBL] [Abstract][Full Text] [Related]
26. In Vivo Evaluation of Site-Specifically PEGylated Chemically Self-Assembled Protein Nanostructures.
Shah R; Petersburg J; Gangar AC; Fegan A; Wagner CR; Kumarapperuma SC
Mol Pharm; 2016 Jul; 13(7):2193-203. PubMed ID: 26985775
[TBL] [Abstract][Full Text] [Related]
27. A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
Mathur D; Root AR; Bugaj-Gaweda B; Bisulco S; Tan X; Fang W; Kearney JC; Lucas J; Guffroy M; Golas J; Rohde CM; Stevens C; Kamperschroer C; Kelleher K; Lawrence-Henderson RF; Upeslacis E; Yao J; Narula J; LaVallie ER; Fernandez DR; Buetow BS; Rosfjord E; Bloom L; King LE; Tchistiakova L; Nguyen A; Sapra P
Clin Cancer Res; 2020 May; 26(9):2188-2202. PubMed ID: 31996389
[TBL] [Abstract][Full Text] [Related]
28. Chemically self-assembled antibody nanostructures as potential drug carriers.
Fegan A; Kumarapperuma SC; Wagner CR
Mol Pharm; 2012 Nov; 9(11):3218-27. PubMed ID: 23013206
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.
Amann M; D'Argouges S; Lorenczewski G; Brischwein K; Kischel R; Lutterbuese R; Mangold S; Rau D; Volkland J; Pflanz S; Raum T; Münz M; Kufer P; Schlereth B; Baeuerle PA; Friedrich M
J Immunother; 2009 Jun; 32(5):452-64. PubMed ID: 19609237
[TBL] [Abstract][Full Text] [Related]
30. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
[TBL] [Abstract][Full Text] [Related]
31. Use of a Single CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Different Solid Tumors.
Lee YG; Marks I; Srinivasarao M; Kanduluru AK; Mahalingam SM; Liu X; Chu H; Low PS
Cancer Res; 2019 Jan; 79(2):387-396. PubMed ID: 30482775
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans.
Amann M; Friedrich M; Lutterbuese P; Vieser E; Lorenczewski G; Petersen L; Brischwein K; Kufer P; Kischel R; Baeuerle PA; Schlereth B
Cancer Immunol Immunother; 2009 Jan; 58(1):95-109. PubMed ID: 18594818
[TBL] [Abstract][Full Text] [Related]
34. Intracerebral bispecific ligand-antibody conjugate increases survival of animals bearing endogenously arising brain tumors.
Patrick TA; Kranz DM; Zachary JF; Roy EJ
Int J Cancer; 1998 Nov; 78(4):470-9. PubMed ID: 9797136
[TBL] [Abstract][Full Text] [Related]
35. Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: association with TH2 cytokines not anergy.
Plain KM; Chen J; Merten S; He XY; Hall BM
Transplantation; 1999 Feb; 67(4):605-13. PubMed ID: 10071035
[TBL] [Abstract][Full Text] [Related]
36. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
37. Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110.
Witthauer J; Schlereth B; Brischwein K; Winter H; Funke I; Jauch KW; Baeuerle P; Mayer B
Breast Cancer Res Treat; 2009 Oct; 117(3):471-81. PubMed ID: 18819003
[TBL] [Abstract][Full Text] [Related]
38. Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager.
Wing A; Fajardo CA; Posey AD; Shaw C; Da T; Young RM; Alemany R; June CH; Guedan S
Cancer Immunol Res; 2018 May; 6(5):605-616. PubMed ID: 29588319
[TBL] [Abstract][Full Text] [Related]
39. Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers.
Loureiro LR; Feldmann A; Bergmann R; Koristka S; Berndt N; Máthé D; Hegedüs N; Szigeti K; Videira PA; Bachmann M; Arndt C
J Exp Clin Cancer Res; 2020 May; 39(1):77. PubMed ID: 32370811
[TBL] [Abstract][Full Text] [Related]
40. Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity.
Maletz K; Kufer P; Mack M; Raum T; Pantel K; Riethmüller G; Gruber R
Int J Cancer; 2001 Aug; 93(3):409-16. PubMed ID: 11433407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
